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Introduction {#cam41108-sec-0001}
============

Human papillomavirus (HPV) is responsible for nearly 1 out of every 20 cancer cases worldwide [1](#cam41108-bib-0001){ref-type="ref"}. HPV‐mediated cellular transformation is achieved primarily through expression of the viral E6 and E7 oncogenes. E6 and E7 act on a variety of targets to induce cell cycle progression. The most critical events for tumor development seem to be the E6‐mediated degradation of the tumor suppressor p53 and induction of telomerase expression, and the E7‐mediated degradation of the retinoblastoma (Rb) family of proteins [2](#cam41108-bib-0002){ref-type="ref"}, [3](#cam41108-bib-0003){ref-type="ref"}, [4](#cam41108-bib-0004){ref-type="ref"}, [5](#cam41108-bib-0005){ref-type="ref"}. p53 and Rb1 are important tumor suppressor proteins that play critical roles in restricting cell cycle progression and maintaining genomic stability. Consequently, E6 and E7 not only enhance cell proliferation, but also the acquisition of additional oncogenic mutations associated with a loss of genomic stability. While HPV‐negative squamous cell carcinomas (SCC) usually have p53 mutations, most HPV‐positive tumors are wild type for both p53 and Rb since both pathways are already inactivated by E6 and E7[6](#cam41108-bib-0006){ref-type="ref"}, [7](#cam41108-bib-0007){ref-type="ref"}, [8](#cam41108-bib-0008){ref-type="ref"}, [9](#cam41108-bib-0009){ref-type="ref"}.

In the United States, Oropharyngeal (OSCC), Cervical (CSCC), Anal (ASCC), and Vulvar (VSCC) squamous cell carcinomas account for the largest number of new HPV‐associated cancers each year [10](#cam41108-bib-0010){ref-type="ref"}. Over 90% of CSCC and ASCC cases are caused by HPV and about 70% of OSCC and VSCC are the result of HPV infection [11](#cam41108-bib-0011){ref-type="ref"}. The management of CSCC, OSCC, ASCC, and VSCC often includes a multimodal treatment strategy that may include chemotherapy, radiation therapy, and surgery. Importantly, platinum‐based chemo‐radiation protocols are similarly effective against ASCC, OSCC, CSCC, and VSCC, suggesting different HPV‐positive cancers may have a common molecular signature and share the same targetable genetic alterations [12](#cam41108-bib-0012){ref-type="ref"}. Tailoring customized treatment regimens based on the molecular profiling of advanced solid tumors has been successful in several early phase trials [13](#cam41108-bib-0013){ref-type="ref"}, [14](#cam41108-bib-0014){ref-type="ref"}, [15](#cam41108-bib-0015){ref-type="ref"}. Therefore, we assessed CSCC, ASCC, OSCC, and VSCC for additional evidence of shared characteristics that could be used to identify potential molecular targets across the spectrum of HPV‐induced cancers.

In this study, we examined biomarker frequency data collected from a commercial molecular profiling service (Caris Life Sciences, Phoenix, AZ). Since p53 mutation is rare in HPV‐positive tumors, p53 status was used as a surrogate for HPV testing [16](#cam41108-bib-0016){ref-type="ref"}, [17](#cam41108-bib-0017){ref-type="ref"}. By analyzing p53 wild type‐SCC of the cervix, anal canal, oropharynx, and vulva, we sought to determine whether different HPV‐positive cancers may respond to common treatment protocols and to identify targetable alterations for patients with these cancers that are advanced, refractory, and difficult to treat. Using a multiplatform approach, this analysis identified several alterations that have the potential to aid in the design of treatment regimens. Our results revealed marked similarities among the HPV‐induced cancers indicating that similar treatment protocols may be beneficial to these cancer types. Importantly, this detailed examination of protein, genetic, and genomic alterations may provide insight for the design of future clinical trials.

Methods {#cam41108-sec-0002}
=======

Patients and multiplatform molecular profiling {#cam41108-sec-0003}
----------------------------------------------

Molecular theranostic biomarkers were assayed by immunohistochemistry, in situ hybridization, and gene sequencing. The biomarker‐drug associations are determined from prospective or retrospective clinical research studies in various solid tumors or are part of the National Comprehensive Cancer Network (NCCN) Biomarkers Compendium. For some biomarkers, therapeutic associations are suggested based on emerging data (e.g., investigational agents in clinical trials). This study includes data from 743 patients with refractory, aggressive, and/or metastatic ASCC, OSCC, CSCC, or VSCC with wild‐type p53. All samples were prospectively assayed by at least one platform (immunohistochemical (IHC), in situ hybridization (ISH), and Sanger/next‐generation sequencing (NGS)) by Caris Life Sciences (2009--2016).

Formalin‐fixed paraffin‐embedded (FFPE) samples were sent by treating physicians for biomarker analysis. Board‐certified pathologists verified sufficient tumor content, specimen quality, and confirmation of diagnosis for all tumors. The manner and scope of testing performed for each patient may have varied based on the physician\'s request, tissue availability, technology advancements (e.g., Sanger vs. NGS), and emerging clinical evidence for theranostic biomarkers.

Immunohistochemistry {#cam41108-sec-0004}
--------------------

Immunohistochemistry (IHC) analysis of 24 proteins was performed by Caris Life Sciences on FFPE tumor samples using commercially available detection kits and automated staining techniques (Benchmark XT; Ventana Medical Systems, Tucson, AZ; and Autostainer‐ LInk 48; Dako, Carpinteria, CA) and manually scored by board‐certified pathologists. IHC analysis, antibody clones, and thresholds used are described in Table [S1](#cam41108-sup-0002){ref-type="supplementary-material"}. IHC for p16 was performed by the Cincinnati Children\'s Hospital pathology core using antibody clone E6H4 (Ventana Medical Systems, Tucson, AZ) and positivity was determined by the authors.

In situ hybridization {#cam41108-sec-0005}
---------------------

c‐MET, c‐MYC, EGFR, HER2, PIK3CA, and TOP2A gene copy number alterations were analyzed using fluorescence in situ hybridization (ISH) and/or chromogenic ISH probes as part of the automated staining techniques (Benchmark XT; Ventana Medical Systems) and automated imaging systems (BioView, Billerica, MA). Copy number alteration was determined as previously described [9](#cam41108-bib-0009){ref-type="ref"}.

Sanger sequencing {#cam41108-sec-0006}
-----------------

Sanger sequencing included selected regions of *BRAF*,*c‐KIT, EGFR, KRAS, NRAS*, and *PIK3CA* and was performed using M13‐linked polymerase chain reaction primers designed to flank and amplify targeted sequences. Polymerase chain reaction products were bidirectionally sequenced using the BigDye Terminator version 1.1 chemistry, and analyzed using the 3730 DNA Analyzer (Applied Biosystems, Grand Island, NY). Sequence traces were analyzed using Mutation Surveyor software version 3.25 (Soft Genetics, State College, PA).

Next‐generation sequencing {#cam41108-sec-0007}
--------------------------

NGS was performed on gDNA from FFPE tumor tissue using the Illumina MiSeq. Specific regions of 48 genes were amplified with the Illumina TruSeq Amplicon Cancer Hotspot panel. All reported mutations were detected with over 99% confidence with an average sequencing depth of over 1000×.

Statistical methods {#cam41108-sec-0008}
-------------------

Retrospective analysis of biomarker frequency was determined using standard descriptive statistics. The two‐tailed Fisher\'s exact test was performed using JMP version 10.0 (SAS Institute, Cary, NC) to test where frequencies differed among cohorts. Bonferroni correction was used to correct for multiple comparisons. A corrected two‐tailed *P* value ≤ 0.05 was determined statistically significant.

Validation and institutional review board {#cam41108-sec-0009}
-----------------------------------------

All methods utilized in this study were clinically validated to Clinical Laboratory Improvement Amendments, College of American Pathologists, and International Organization for Standardization (ISO) 15,189. This retrospective analysis utilized previously collected, de‐identified data created under the Caris honestbroker policy and followed consultation with the Western Institutional Review Board (IRB), which is the IRB of record for Caris Life Sciences. The project was determined to be exempt from IRB oversight and consent requirements were waived.

Results {#cam41108-sec-0010}
=======

Patient and Tumor characteristics {#cam41108-sec-0011}
---------------------------------

ASCC, CSCC, OSCC, and VSCC tumors were screened for p53 status as a surrogate for HPV testing. A total of 743 tumors with wild‐type p53 status were identified for this study and are described in Table [1](#cam41108-tbl-0001){ref-type="table-wrap"}. While over 90% of all ASCC and CSCC cases result from HPV infection, only 70% of OSCC cases are HPV positive and tobacco or alcohol use likely contribute to the other 30% [11](#cam41108-bib-0011){ref-type="ref"}, [18](#cam41108-bib-0018){ref-type="ref"}. To further validate that the cohorts contained HPV‐positive samples, OSCC tissue was also tested for p16 immunoreactivity, which is a reliable, clinically utilized indicator of HPV positivity [19](#cam41108-bib-0019){ref-type="ref"}. Of the 147 p53 wild‐type OSCC specimens, 128 had slides of tissue available for p16 IHC. Over 97% of the OSCC samples tested (125/128) were positive for p16 expression (Table [S2](#cam41108-sup-0003){ref-type="supplementary-material"}). CSCC samples accounted for approximately 42% (*n* = 314) of all tumors. ASCC, OSCC, and VSCC accounted for 27% (*n* = 199), 20% (*n* = 147), and 11% (*n* = 83) of samples, respectively. The ASCC cohort was predominantly female (64%), while the male sex made up the majority of the OSCC cohort (84%). Of the 743 tumor samples, 337 (45%) were from primary tumors and 406 (55%) were metastatic.

###### 

Clinicopathological characteristics of 743 patients with molecularly profiled p53 wild‐type squamous cell carcinoma

                               ASCC          CSCC         OSCC          VSCC
  ---------------------------- ------------- ------------ ------------- ------------
  Male (%)                     70 (35.2%)    0 (0%)       124 (84.4%)   0 (0%)
  Average age, years           59            N/A          58            N/A
  Minimum age                  31            N/A          27            N/A
  Maximum age                  88            N/A          88            N/A
  Site of tumor profiled (%)                                            
  Primary site                 28 (40%)      N/A          67 (54%)      N/A
  Metastatic site              42 (60%)      N/A          57 (46%)      N/A
  Female (%)                   129 (64.8%)   314 (100%)   23 (15.6%)    83 (100%)
  Average age, years           59            50           61            61
  Minimum age                  35            24           26            29
  Maximum age                  89            90           79            85
  Site of tumor profiled (%)                                            
  Primary site                 36 (27.9%)    141 (45%)    15 (65.2%)    50 (60.2%)
  Metastatic site              93 (72.1%)    173 (55%)    8 (34.8%)     33 (39.8%)
  Total                        199           314          147           83
  Site of tumor profiled (%)                                            
  Primary site                 64 (32.2%)    141 (45%)    82 (55.8%)    50 (60.2%)
  Metastatic site              135 (67.8%)   173 (55%)    65 (44.2%)    33 (39.8%)
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Multiplatform biomarker detection {#cam41108-sec-0012}
---------------------------------

A total of 79 biomarkers were evaluated in this study using a combination of next‐generation (NGS) and Sanger sequencing, Immunohistochemistry (IHC), and in situ hybridization (ISH). However, due to variation in the number of biomarkers tested for each sample, the total number of patients assayed differs for each biomarker. The total numbers of patients tested for each biomarker are listed in Tables [2](#cam41108-tbl-0002){ref-type="table-wrap"} and [3](#cam41108-tbl-0003){ref-type="table-wrap"}. Only biomarkers that had been tested in all four types of SCC were included in further analysis. Therefore, IHC testing of BCRP, c‐kit, COX‐2, and MRP1 as well as ISH testing of *c‐MYC* and *PIK3CA* were not compared across types of SCC since there were no data from one or more SCC cohorts (Fig. [1](#cam41108-fig-0001){ref-type="fig"}).

###### 

Alteration frequency of predictive biomarkers measured by immunohistochemistry and in situ hybridization

  Method                    Biomarker   Number of samples tested   Number of samples altered   \% altered
  ------------------------- ----------- -------------------------- --------------------------- ------------
  IHC (high expression)     ALK         123                        0                           0.0
  AR                        648         29                         4.5                         
  BCRP                      9           1                          11.1                        
  c‐kit                     104         2                          1.9                         
  cMET                      538         84                         15.6                        
  COX‐2                     10          3                          30.0                        
  EGFR                      273         254                        93.0                        
  ER                        680         104                        15.3                        
  HER2                      700         13                         1.9                         
  MRP1                      102         91                         89.2                        
  PD‐1                      326         239                        73.3                        
  PD‐L1 (SP142)             368         81                         22.0                        
  PGP                       588         11                         1.9                         
  PR                        677         23                         3.4                         
  RRM1                      596         386                        64.8                        
  SPARC M                   506         146                        28.9                        
  SPARC P                   546         170                        31.1                        
  TLE3                      548         248                        45.3                        
  TOP2A                     661         626                        94.7                        
  TOPO1                     679         443                        65.2                        
  IHC (low/no expression)   ERCC1       296                        122                         41.2
  MGMT                      669         447                        66.8                        
  PTEN                      694         412                        59.4                        
  TS                        690         460                        66.7                        
  TUBB3                     571         138                        24.2                        
  ISH (amplification)       c‐MET       421                        1                           0.2
  c‐MYC                     4           1                          25.0                        
  EGFR                      85          7                          8.2                         
  HER2                      574         13                         2.3                         
  PIK3CA                    3           3                          100.0                       
  TOP2A                     33          0                          0.0                         
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###### 

Mutation frequency as determined by next‐generation sequencing

  Biomarker   Number tested   Number altered   \% altered
  ----------- --------------- ---------------- ------------
  ABL1        442             0                0.0
  AKT1        451             9                2.0
  ALK         453             0                0.0
  APC         452             1                0.2
  ATM         442             1                0.2
  BRAF        537             0                0.0
  BRCA1       221             2                0.9
  BRCA2       222             3                1.4
  CDH1        452             0                0.0
  c‐KIT       507             0                0.0
  cMET        453             0                0.0
  CSF1R       451             0                0.0
  CTNNB1      453             8                1.8
  EGFR        458             0                0.0
  ERBB2       448             0                0.0
  ERBB4       449             0                0.0
  FBXW7       450             29               6.4
  FGFR1       453             0                0.0
  FGFR2       452             0                0.0
  FLT3        452             0                0.0
  GNA11       403             0                0.0
  GNAQ        350             0                0.0
  GNAS        453             1                0.2
  HNF1A       408             2                0.5
  HRAS        373             3                0.8
  IDH1        452             0                0.0
  JAK2        453             0                0.0
  JAK3        452             0                0.0
  KDR         453             0                0.0
  KRAS        567             11               1.9
  MLH1        451             0                0.0
  MPL         449             0                0.0
  NOTCH1      448             0                0.0
  NPM1        451             0                0.0
  NRAS        502             2                0.4
  PDGFRA      451             0                0.0
  PIK3CA      527             136              25.8
  PTEN        432             14               3.2
  PTPN11      452             0                0.0
  RB1         445             3                0.7
  RET         442             0                0.0
  SMAD4       452             1                0.2
  SMARCB1     451             0                0.0
  SMO         361             0                0.0
  STK11       434             2                0.5
  TP53        446             0                0.0
  VHL         405             0                0.0
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![HPV‐positive squamous cell carcinomas have similar rates of expression profile alteration. (A) IHC revealed similar rates of biomarker detection in ASCC,CSCC,OSCC, and VSCC tumors. Positivity is indicative of high expression unless denoted. \# indicates low or no expression as positive. (B) Frequency of gene amplification across SCCs as determined by ISH. *P* \< 0.05 (\*); *P* \< 0.001 (\*\*).](CAM4-6-1673-g001){#cam41108-fig-0001}

Gene expression and copy number alteration {#cam41108-sec-0013}
------------------------------------------

Total rates of gene expression as measured by IHC and gene copy number alteration by ISH are listed in Table [2](#cam41108-tbl-0002){ref-type="table-wrap"}. IHC revealed the most frequently altered proteins to be: TOP2A (94.7%), EGFR (93%), MRP1 (89.2%), and PD‐1 (73.3%), which were all highly expressed. Loss of MGMT (66.8%), TS (66.7%), and PTEN (59.4%) expression also occurred at high frequency. ISH showed the *PIK3CA* and *c‐MYC* genes were amplified in 100% and 25% of tested samples, respectively. However, only three patients were tested for *PIK3CA* and only four patients were tested for *c‐MYC* amplification. No other amplifications were detected at high rates. The only other amplifications detected were *EGFR, HER2*, and *c‐MET* which occurred in less than 10% of tested samples.

Markedly similar expression profiles were detected between ASCC, CSCC, OSCC, and VSCC (Fig. [1](#cam41108-fig-0001){ref-type="fig"}A). In all four cohorts, IHC most commonly revealed high expression of EGFR, which ranged from detection rates of 89.8% in CSCC to 97.9% in OSCC, and TOP2A, which ranged from detection rates of 86.5% in VSCC to 98.4% in OSCC. While EGFR detection was common, ALK expression was not detected in any of the cohorts. The biomarker with the largest variance of detection among the four types of SCC was SPARC P. Over 42% of CSCC samples were positive for SPARC P (*P* \< 0.001), while only 13.7% of OSCC samples were positive (*P* \< 0.001).

ERCC1 expression was lost in over half of ASCC samples and over 43% of OSCC and VSCC samples. However, only 26.5% of CSCC samples lost ERCC1 expression (*P* = 0.024). MRP1 was detected at high frequency in ASCC (97.7%), OSCC (86.2%), and VSCC (79.3%) though no cases of CSCC were tested for MRP1 by IHC. The detection rates of RRM1 and TLE3 expression were also consistent across cohorts and ranged from 56% to 66% and 42% to 52%, respectively. Loss of PTEN, MGMT, and TS expression was also consistent among all four groups. Rates of PTEN loss ranged from 51.2% in VSCC to 64.1% in CSCC. MGMT and TS loss rates ranged from 53% to 73%.

The PD‐1/PD‐L1 immunomodulatory axis was also evaluated across the four cohorts of SCC. Tumor infiltrating lymphocytes were examined for PD‐1 expression and tumor cells were tested for PD‐L1 expression. Positivity for PD‐1 was more common than for PD‐L1. Rates of PD‐1 expression positivity ranged from 63.3% in ASCC to 80.6% in OSCC, while PD‐ L1 expression positivity rates ranged from only 13.3% in VSCC to 24.9% in CSCC.

Only c‐MET, EGFR, HER2, and TOP2A were examined for gene copy number alterations in samples from all four cohorts. Gene amplification was found by ISH to be an uncommon event, regardless of cancer type (Fig. [1](#cam41108-fig-0001){ref-type="fig"}B). The most commonly amplified gene was *EGFR* which was amplified in 9.1% of OSCC, 8.1% of ASCC, 8% of VSCC, and 0% of CSCC cases. Amplification of *c‐MET* was detected only in a single case of VSCC (2.3%), while *TOP2A* amplification was not found in any samples. *PIK3CA* amplification was examined in only two cases of ASCC and one case of OSCC, all of which tested positive, while *c‐MYC* copy number increase was detected in one of three tested OSCC samples and was not amplified in the one ASCC sample tested.

Mutation analysis {#cam41108-sec-0014}
-----------------

Total rates of variant detection for the 47 genes analyzed for mutation are shown in Table [3](#cam41108-tbl-0003){ref-type="table-wrap"}. Specific allele changes are listed in Table [S3](#cam41108-sup-0004){ref-type="supplementary-material"} and mutation profiles by patient are listed in Table [S4](#cam41108-sup-0005){ref-type="supplementary-material"}. The most frequently mutated gene was *PIK3CA* which was altered in 25.8% of SCC patients tested. The next most commonly mutated genes were *FBXW7* (6.4%) and *PTEN* (3.2%). No known oncogenic mutations were detected in the following genes in any of the four cohorts: *ABL1, ALK, BRAF, CDH1, c‐KIT, c‐MET, CSF1R, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FLT3, GNA11, GNAQ, IDH1, JAK2, JAK3, KDR, MLH1, MPL, NOTCH1, NPM1, PDGFRA, PTPN11, RET, SMARCB1, SMO*, and *VHL* (Table [3](#cam41108-tbl-0003){ref-type="table-wrap"}).

*PIK3CA* was the most commonly mutated gene in all four types of SCC, occurring at a rate of 24.8% in ASCC, 30.5% in CSCC, 22.3% in OSCC, and 10.2% in VSCC (Fig. [2](#cam41108-fig-0002){ref-type="fig"}). Other than *PIK3CA* mutation, mutational events were relatively uncommon in all four cohorts. The next most commonly mutated gene in ASCC and OSCC was *FBXW7* (12%). However, only 3% of CSCC samples were mutant and no *FBXW7* mutations were detected in VSCC samples. The second most common mutation in VSCC was *BRCA2* (6.7%), which was not detected in ASCC or OSCC and found in only 1.5% of CSCC cases. The only gene found mutated within all four cohorts, aside from *PIK3CA*, was *AKT1*, albeit at a very low rate (0.8%‐5.5%). No differences in mutation rates were statistically significant between the four cohorts.

![Mutation of biomarker genes occurs in similar proportions of different HPV+ squamous cell carcinomas. Mutations of clinical significance were identified through sequencing of 47 genes. Genes that were not mutated in any of the four SCC types were not included in this figure. No difference between cohorts was statistically significant.](CAM4-6-1673-g002){#cam41108-fig-0002}

PI3K pathway {#cam41108-sec-0015}
------------

Phosphoinositide 3‐kinase (PI3K) is a heterodimer lipid kinase that, when activated by a receptor tyrosine kinase, converts PIP~2~ to PIP~3~ [20](#cam41108-bib-0020){ref-type="ref"}. The p110*α* catalytic subunit of the enzyme is encoded by the *PIK3CA* gene. PIP~3~ recruits AKT to the membrane, where it can be activated and promote proliferation, growth, and survival through activation of downstream targets such as mTOR. The phosphatase PTEN acts antagonistically to PI3K, dephosphorylating PIP~3~ to PIP~2~ and preventing AKT recruitment and activation [21](#cam41108-bib-0021){ref-type="ref"}, [22](#cam41108-bib-0022){ref-type="ref"}.

The specific site of a *PIK3CA* mutation is potentially an important predictive indicator for tumor growth and response to treatment. In urothelial carcinoma, mutations in the kinase domain of the protein result in increased AKT activation, compared to helical domain mutations [23](#cam41108-bib-0023){ref-type="ref"}. Additionally, specific *PIK3CA* mutations may have implications for treatment efficacy. Patients with advanced solid tumors harboring an H1047R mutation, which is in the kinase domain, benefit from treatment with a PI3K/AKT/mTOR inhibitor more than patients with other *PIK3CA* mutations [24](#cam41108-bib-0024){ref-type="ref"} Examination of specific *PIK3CA* mutation loci revealed that all four types of SCC had similar distributions of mutation sites within the *PIK3CA* gene (Fig. [3](#cam41108-fig-0003){ref-type="fig"}A). In each of the four cohorts, E545 was the most commonly mutated site and a missense mutation at either E542 or E545 in the helical domain of the protein accounted for 75% of all *PIK3CA* mutations. Mutations in the kinase domain were not common as they accounted for 12% of the *PIK3CA* mutations for OSCC and ASCC. In CSCC, only 7% of *PIK3CA* mutations were in the kinase domain and none were detected in VSCC. However, there were only five cases of *PIK3CA*‐mutant VSCC in the study. Interestingly, mutation of E726 in exon 13, which is of unknown clinical significance, was detected in all four cohorts.

![Different HPV+ squamous cell carcinomas have similar PIK3CA mutational landscapes. (A) Frequency and distribution of mutations within the PIK3CA gene as determined by NGS and Sanger sequencing. Corresponding protein domains are shown below the graph. (B) Percent of PIK3CA‐mutant tumors with co‐occurring loss of PTEN as determined by IHC. (C) Percent of samples with PIK3CA mutation stratified by disease state. For primary tumors, *n* = 50 (ASCC), *n* = 113 (CSCC), *n* = 56 (OSCC), *n* = 29 (VSCC). For regional metastases, *n* = 35 (ASCC), *n* = 85 (CSCC), *n* = 12 (OSCC), *n* = 3 (VSCC). For samples from lymph nodes, *n* = 11 (ASCC), *n* = 25 (CSCC), *n* = 9 (OSCC), *n* = 14 (VSCC). For distant metastases, *n* = 27 (ASCC), *n* = 32 (CSCC), *n* = 13 (OSCC), *n* = 1 (VSCC). (D) Percent of PIK3CA‐mutant samples with co‐occurring loss of PTEN expression. For primary tumors, *n* = 10 (ASCC), *n* = 32 (CSCC), *n* = 8 (OSCC), *n* = 2 (VSCC). For regional metastases, *n* = 13 (ASCC), *n* = 28 (CSCC), *n* = 3 (OSCC), *n* = 0 (VSCC). For samples from lymph nodes, *n* = 2 (ASCC), *n* = 8 (CSCC), *n* = 4 (OSCC), *n* = 2 (VSCC). For distant metastases, *n* = 6 (ASCC), *n* = 7 (CSCC), *n* = 3 (OSCC), *n* = 1 (VSCC). No differences were statistically significant after correcting for multiple comparisons.](CAM4-6-1673-g003){#cam41108-fig-0003}

PI3 kinase inhibitors are currently in clinical trials and loss of PTEN expression has emerged as an indicator of resistance to PI3K inhibition [25](#cam41108-bib-0025){ref-type="ref"}. It was previously reported that 24% of head and neck SCC with a PI3K mutation also exhibit loss of PTEN expression [9](#cam41108-bib-0009){ref-type="ref"}. HPV‐positive tumors exhibited much higher rates of co‐occurrence in all four cohorts (Fig. [3](#cam41108-fig-0003){ref-type="fig"}B). In *PIK3CA*‐mutant samples, concurrent PTEN loss was found in 82.4% (ASCC), 80% (VSCC), 66.3% (CSCC), and 56.5% (OSCC) of cases.

*PIK3CA* mutation status and PTEN expression was then examined based on disease state for each of the four SCCs. Disease state was classified depending upon whether the sample was collected from the primary tumor, regional metastasis into the surrounding soft tissue, lymph node, or distant metastasis. *PIK3CA* mutation rate in ASCC ranged from 20% in specimens from the primary tumor site to 37% in samples from regional metastases (Fig. [3](#cam41108-fig-0003){ref-type="fig"}C). The mutation rate in CSCC ranged from 25% in distant metastases to 34% in regional metastases. OSCC mutation rates were lowest in tissue from the primary tumors (16%) and highest in samples collected from the lymph nodes (44%). VSCC had the widest range of *PIK3CA* mutation rates with no mutations detected in regional metastases, while the only sample from a case of distant metastasis was positive for *PIK3CA* mutation. Only 47 VSCC samples could be included for comparison of *PIK3CA* mutation by disease state and of these, only three were of regional metastases. No differences were statistically significant after correction for multiple comparisons.

*PIK3CA*‐mutant samples stratified by disease state were also examined for concurrent loss of PTEN (Fig. [3](#cam41108-fig-0003){ref-type="fig"}D). In cases of *PIK3CA*‐mutant ASCC, PTEN loss was detected in 77% of samples from regional metastases, 83% of distant metastases, 90% of primary tumors, and 100% of samples from lymph nodes. For CSCC, *PIK3CA*‐mutant samples from lymph nodes had the lowest rate of PTEN loss (63%), while samples from regional metastases had the highest (82%). OSCC samples ranged from 50% in lymph node samples to 67% in samples from regional and distant metastases. *PIK3CA*‐mutation was not detected in any VSCC samples of regional metastases; so, concurrent PTEN loss could not be examined. Rates of PTEN loss ranged from 50% in primary tumor samples to 100% in samples from lymph nodes and distant metastases. Despite the wide range of PTEN loss rates in VSCC, there were only five total *PIK3CA*‐mutant samples and no differences were statistically significant.

PD‐1/PD‐L1 {#cam41108-sec-0016}
----------

With the emergence of anti‐PD‐1 therapies, PD‐L1 has become an important biomarker in an attempt to predict what patients would benefit from anti‐PD‐1 treatments [26](#cam41108-bib-0026){ref-type="ref"}. In all four cohorts, PD‐1 expression on tumor infiltrating lymphocytes (TIL) was much more common than PD‐L1 expression on tumor cells (Fig. [1](#cam41108-fig-0001){ref-type="fig"}). PD‐1 and PD‐L1 expression were analyzed by disease state for each type of SCC (Fig. [4](#cam41108-fig-0004){ref-type="fig"}A, B). In ASCC, PD‐1 positivity on TIL ranged from 40% in samples from lymph nodes to 75% in regional metastases. For CSCC, PD‐1 positivity was more common in primary tumors (79.7%) and regional metastases (77.8%) than in samples from lymph nodes (57.8%) and distant metastases (59.1%). Over 90% of OSCC samples from primary tumors and lymph nodes were positive for TIL expression of PD‐1. Positivity rates for regional and distant metastases were 66.7% and 54.5%, respectively. Two out of two VSCC samples from regional metastases tested for PD‐1were positive for expression on TIL, while neither of the two samples tested from distant metastases were positive. VSCC samples from primary tumors (73.3%) and lymph nodes (77.8%) were similar in terms of PD‐1 expression. No differences in PD‐1 expression were statistically significant. Additionally, there was not a statistically significant difference in PD‐1 expression between primary and metastatic tumors in general (Fig. [S1](#cam41108-sup-0001){ref-type="supplementary-material"}).

![PD‐1 and PD‐L1 expression in different squamous cell carcinomas stratified by disease state. (A) Percent of samples positive for PD‐1 expression on tumor infiltrating lymphocytes as determined by IHC. For primary tumors, *n* = 25 (ASCC), *n* = 79 (CSCC), *n* = 31 (OSCC), *n* = 15 (VSCC). For regional metastases, *n* = 20 (ASCC), *n* = 54 (CSCC), *n* = 9 (OSCC), *n* = 2 (VSCC). For samples from lymph nodes, *n* = 5 (ASCC), *n* = 19 (CSCC), *n* = 11 (OSCC), *n* = 9 (VSCC). For distant metastases, *n* = 10 (ASCC), *n* = 22 (CSCC), *n* = 11 (OSCC), *n* = 2 (VSCC). (B) Percent of tumor samples positive for PD‐L1 expression by IHC. For primary tumors, *n* = 33 (ASCC), *n* = 90 (CSCC), *n* = 34 (OSCC), *n* = 16 (VSCC). For regional metastases, *n* = 23 (ASCC), *n* = 63 (CSCC), *n* = 10 (OSCC), *n* = 3 (VSCC). For samples from lymph nodes, *n* = 5 (ASCC), *n* = 24 (CSCC), *n* = 11 (OSCC), *n* = 9 (VSCC). For distant metastases, *n* = 10 (ASCC), *n* = 24 (CSCC), *n* = 11 (OSCC), *n* = 2 (VSCC).](CAM4-6-1673-g004){#cam41108-fig-0004}

Tumor cell expression of PD‐L1 was also tested. Within primary tumors and regional metastases, PD‐L1 expression was similar in the different types of SCC. In primary tumors, PD‐L1 expression was most common in CSCC (26.7%) and least common in OSCC (14.7%). In regional metastases, ASCC, CSCC, and OSCC positivity rates ranged from 20% (OSCC) to 23.9%. No VSCC samples of regional metastases were positive for PD‐L1 expression, though only three samples were tested. None of the nine VSCC samples from lymph nodes or two samples from distant metastases were positive for PD‐L1 expression either. Rates of positivity within lymph node samples were 40% (ASCC), 12.5% (CSCC), and 36.4% (OSCC). For distant metastases, none of the 11 OSCC samples tested were positive for PD‐L1 expression. ASCC and CSCC samples had positivity rates of 10% and 29.1%, respectively. No differences in rates of PD‐L1 expression were statistically significant.

Discussion {#cam41108-sec-0017}
==========

All four types of SCC showed a strikingly similar molecular profile. Chemotherapeutic treatment options are similar for ASCC, CSCC, OSCC, and VSCC with 5‐fluorouracil and platinum‐based therapies commonly used across all four types of cancer. However, CSCC currently has more treatment options than the other three types of SCC evaluated (Table [4](#cam41108-tbl-0004){ref-type="table-wrap"}). The similarities between the four cohorts suggest that treatments shown to be effective in HPV‐positive CSCC may also be beneficial in the treatment of ASCC, OSCC, and VSCC. Low RRM1 expression is used to predict gemcitabine efficacy in CSCC (Table [4](#cam41108-tbl-0004){ref-type="table-wrap"}) and is common in all four cohorts (Fig. [1](#cam41108-fig-0001){ref-type="fig"}A), suggesting gemcitabine may be beneficial beyond just CSCC. Taxanes are currently used to treat CSCC, OSCC, and VSCC and are currently in clinical trials for use in ASCC, where the results are very promising, particularly in HPV‐positive cases [27](#cam41108-bib-0027){ref-type="ref"}.

###### 

Comparison of cancer agents according to NCCN guidelines for HPV‐induced cancers

  Drug Type             Predictive Biomarkers          ASCC                                 CSCC                           OSCC                      VSCC
  --------------------- ------------------------------ ------------------------------------ ------------------------------ ------------------------- -----------
  Cytotoxic Therapies   ERCC1, BRCA1/2                 cisplatin                            cisplatin, carboplatin         cisplatin, carboplatin    cisplatin
  TS                    5‐fluorouracil, capecitabine   5‐fluorouracil, pemetrexed           5‐fluorouracil, capecitabine   5‐fluorouracil            
  TUBB3/TLE3/PGP                                       paclitaxel, docetaxel, vinorelbine   paclitaxel, docetaxel          paclitaxel, vinorelbine   
  TOPO1                                                topotecan, irinotecan                                                                         
  RRM1                                                 gemcitabine                                                                                   
  BRCA1/2               mitomycin‐C                    mitomycin‐C                                                         mitomycin‐C               
  Targeted Therapies    none identified                                                     bevacizumab                    cetuximab                 

John Wiley & Sons, Ltd

In addition to cytotoxic agents, targeted therapies such as the anti‐EGFR antibody, cetuximab, are also being used. However, there are currently no recognized biomarkers to predict which patients will benefit from these treatments [28](#cam41108-bib-0028){ref-type="ref"} (Table [4](#cam41108-tbl-0004){ref-type="table-wrap"}). While, *EGFR* amplification was not common, the vast majority of samples in all four cohorts highly expressed EGFR. Surprisingly, *EGFR* copy number increase is not predictive of cetuximab efficacy [29](#cam41108-bib-0029){ref-type="ref"}. In non‐small‐cell lung cancer, EGFR expression level is predictive of cetuximab benefit; however, for head and neck SCC and colon cancer, even EGFR expression level is not informative in determining if cetuximab will improve patient outcome [30](#cam41108-bib-0030){ref-type="ref"}, [31](#cam41108-bib-0031){ref-type="ref"}. Rather, evaluation of downstream signaling components (e.g., members of PI3K pathway) or other receptor tyrosine kinases (e.g., c‐MET, ROS1, ALK) seems to be more informative in predicting efficacy of anti‐EGFR therapy [32](#cam41108-bib-0032){ref-type="ref"}, [33](#cam41108-bib-0033){ref-type="ref"}, [34](#cam41108-bib-0034){ref-type="ref"}, [35](#cam41108-bib-0035){ref-type="ref"}, [36](#cam41108-bib-0036){ref-type="ref"}, [37](#cam41108-bib-0037){ref-type="ref"}. More work is needed to determine what molecular signatures are indicative of a positive response to anti‐EGFR treatments.

The rate of EGFR IHC positivity in our OSCC cohort is higher than reported in other HPV‐positive OSCC cohorts [38](#cam41108-bib-0038){ref-type="ref"}, [39](#cam41108-bib-0039){ref-type="ref"}, [40](#cam41108-bib-0040){ref-type="ref"}. This is likely because our data are generated from samples submitted to a commercial molecular profiling service. Samples from tumors that respond well to chemotherapy are unlikely to be submitted for molecular profiling and consequently, our cohort may contain a disproportionately high number of aggressive, treatment‐resistant tumors that have already been treated with chemotherapy. EGFR expression is associated with a poor prognosis in OSCC [38](#cam41108-bib-0038){ref-type="ref"}, further suggesting that our data describe the molecular profile of aggressive, treatment‐resistant HPV‐positive SCC, rather that HPV‐positive SCC in general.

IHC positivity was even more common for TOP2a than for EGFR. In hepatocellular carcinoma, TOP2a overexpression is associated with chemoresistance. However, there is some evidence that etoposide may be beneficial to these patients in combination with doxorubicin, another topoisomerase II inhibitor [41](#cam41108-bib-0041){ref-type="ref"}. In a mouse model of lymphoma, high TOP2a expression is an indicator of doxorubicin efficacy, while low TOP1 expression is associated with resistance to the topoisomerase I inhibitor camptothecin and increased responsiveness to doxorubicin [42](#cam41108-bib-0042){ref-type="ref"}. Multiple studies have found that TOP1 expression level is predictive of whether colon cancer patients will benefit from irinotecan [43](#cam41108-bib-0043){ref-type="ref"}, [44](#cam41108-bib-0044){ref-type="ref"} and possibly predictive of oxaliplatin efficacy [43](#cam41108-bib-0043){ref-type="ref"}. Interestingly, while TOP1 expression level has shown great predictive value, *TOP1* copy number was not found to be a predictive biomarker for irinotecan [44](#cam41108-bib-0044){ref-type="ref"}. There have been several reports of using irinotecan and cetuximab as a successful combination therapy for ASCC, particularly in *KRAS* wild‐type patients [45](#cam41108-bib-0045){ref-type="ref"}, [46](#cam41108-bib-0046){ref-type="ref"}. These reports are in agreement with our finding that the majority of ASCC patients have high expression of both EGFR and TOP1, while also highlighting the potential importance of using biomarkers downstream of EGFR to predict the benefits of cetuximab. It remains to be seen if treatment regimens targeting EGFR and topoisomerase I are effective in CSCC, VSCC, and OSCC, but the similarities we have found between the four cohorts provides rationale for further investigation.

While we found TOP2a to be highly expressed in almost all cases of CSCC, in a trial of CSCC patients, orally administered etoposide as a second‐line therapy was only effective in 11% of patients [47](#cam41108-bib-0047){ref-type="ref"}, indicating that TOP2a expression status alone may not be predictive of response to topoisomerase II poisons. This is not unexpected considering that most patients in this study had high expression of both TOP2a and TOP1.

In hepatocellular carcinoma, TOP2a overexpression is associated with chemoresistance. However, there is some evidence that etoposide may be beneficial to these patients in combination with doxorubicin, another topoisomerase II inhibitor [41](#cam41108-bib-0041){ref-type="ref"}. In a mouse model of lymphoma, high TOP2a expression is an indicator of doxorubicin efficacy, while low TOP1 expression is associated with resistance to the topoisomerase I inhibitor camptothecin and increased responsiveness to doxorubicin [42](#cam41108-bib-0042){ref-type="ref"}. Multiple studies have found that TOP1 expression level is predictive of whether a colon cancer patient will benefit from irinotecan [43](#cam41108-bib-0043){ref-type="ref"}, [44](#cam41108-bib-0044){ref-type="ref"} and possibly predictive of oxaliplatin efficacy [43](#cam41108-bib-0043){ref-type="ref"}. Interestingly, while TOP1 expression level has shown great predictive value, *TOP1* copy number was not found to be a predictive biomarker for irinotecan [44](#cam41108-bib-0044){ref-type="ref"}.

High expression of the nucleotide excision repair and DNA interstrand crosslink repair protein, ERCC1, is an established marker for resistance to platinum‐based chemotherapy [48](#cam41108-bib-0048){ref-type="ref"}, [49](#cam41108-bib-0049){ref-type="ref"}, [50](#cam41108-bib-0050){ref-type="ref"}. Over 40% of samples in this study displayed low ERCC1 expression. ERCC1 also seems to be necessary for homologous recombination, suggesting PARP inhibitors may provide additional therapeutic benefit to these patients [51](#cam41108-bib-0051){ref-type="ref"}. In vitro work suggests that the addition of a PARP inhibitor to a platinum‐based treatment strategy may be beneficial when tumors have low ERCC1 expression [52](#cam41108-bib-0052){ref-type="ref"}.

The majority of samples in all four cohorts displayed low MGMT expression. Loss of MGMT expression is an established indicator of response to the DNA methylating agent, temozolomide. While previous studies found that temozolomide offers little value outside of treating brain tumors, most studies did not select patients based on MGMT status [53](#cam41108-bib-0053){ref-type="ref"}. The use of MGMT as a biomarker for determining temozolomide utility outside of brain tumors has shown promise in case reports of colorectal cancer patients with low MGMT expression [54](#cam41108-bib-0054){ref-type="ref"}. Further investigation is needed to determine if MGMT is a useful indicator of response to temozolomide in HPV‐positive SCC.

Tumors expressing PD‐L1 are thought to have a better chance of responding to anti‐PD‐1 therapy, while the value of PD‐1 expression is less clear. Additional factors may play into determining the benefit of anti‐PD‐1 therapy, since some patients testing negative for PD‐L1 have benefited greatly from immune checkpoint inhibitors [26](#cam41108-bib-0026){ref-type="ref"}, [55](#cam41108-bib-0055){ref-type="ref"}, [56](#cam41108-bib-0056){ref-type="ref"}, [57](#cam41108-bib-0057){ref-type="ref"}, [58](#cam41108-bib-0058){ref-type="ref"}. Additional work is needed to determine the predictive value of PD1 and PD‐L1, specifically in HPV‐induced SCC. Immunotherapies may be particularly important for treating this type of cancer since there are few targeted therapies available as options for these patients (Table [4](#cam41108-tbl-0004){ref-type="table-wrap"}). Furthermore, most PIK3CA mutations in these tumors occur outside of the kinase domain and are accompanied by concurrent loss of PTEN expression (Fig. [3](#cam41108-fig-0003){ref-type="fig"}), making these tumors potentially poor responders to PI3K inhibitors and further highlighting the importance of determining the predictive value of PD‐1 and PD‐L1 with regard to anti‐PD1 therapy.

The similar molecular profiles of the four cohorts indicate that treatment strategies may be similarly efficacious across HPV‐positive cancers. The low rate of oncogene mutation detected in the tumor samples suggests that there is limited potential for targeted therapies in HPV‐positive SCC and emphasizes the importance of identifying reliable biomarkers for current and future cytotoxic and immunotherapies.
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###### 

**Figure S1.** Protein expression does not significantly differ between primary and metastatic tumors**.** Tumors from the primary and metastatic sites were compared for expression of proteins for which data were available for all four type of SCC. For ASCC *n* ≥ 25 (primary) and *n* ≥ 35 (metastatic). For CSCC *n* ≥ 42 (primary) and *n* ≥ 72 (metastatic). For OSCC *n* ≥ 22 (primary) and *n* ≥ 28 (metastatic). For VSCC *n* ≥ 15 (primary) and *n* ≥ 12 (metastatic).
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Click here for additional data file.
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**Table S1.** Probe and Threshold information for IHC and ISH
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Click here for additional data file.
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**Table S2.** P16 expression status of OSCC patient samples determined by IHC.
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Click here for additional data file.
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**Table S3.** Targeted sequencing results for patient samples tested.
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Click here for additional data file.

###### 

**Table S4.** Summary of IHC, ISH, and sequencing results for each patient sample

###### 

Click here for additional data file.
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